An azirine solid-state photodegradant of the CCR2/CCR5 dual antagonist BMS-813160

被引：1
|
作者：
Ayers, Sloan [1 ]
La Cruz, Thomas [1 ]
Park, Hyunsoo [2 ]
Ramirez, Antonio [1 ]
Hritzko, Benjamin [1 ]
Sarjeant, Amy [2 ]
Lin, Ziqing [1 ]
Zaretsky, Serge [1 ]
Huang, Yande [1 ]
Zang, Jia [1 ]
Yuill, Elizabeth M. [1 ]
Fenster, Michael D. B. [1 ]
机构：
[1] Bristol Myers Squibb Co, Chem Proc Dev, New Brunswick, NJ 08903 USA
[2] Bristol Myers Squibb Co, Drug Prod Dev, New Brunswick, NJ 08903 USA
来源：
TETRAHEDRON LETTERS | 2022年 / 110卷
关键词：
Azirine; Photodegradation; NMR Spectroscopy; BMS-813160; DEGRADATION; IMPURITIES; CAPTURE;
D O I：
10.1016/j.tetlet.2022.154164
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
The synthesis of the CCR2/5 dual chemokine antagonist BMS-813160 (1) presented a number of interesting impurity and degradant structure elucidation challenges. This publication will focus on the structure elucidation of the solid-state photodegradant of 1 which produced an unexpected stable azirine species. The structure was elucidated by mass spectrometry and NMR, with confirmation by single-crystal X-ray crystallography. (C) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice
    Mack, M
    Cihak, J
    Simonis, C
    Luckow, B
    Proudfoot, AEI
    Plachy, J
    Brühl, H
    Frink, M
    Anders, HJ
    Vielhauer, V
    Pfirstinger, J
    Stangassinger, M
    Schlöndorff, D
    JOURNAL OF IMMUNOLOGY, 2001, 166 (07): : 4697 - 4704
  • [32] Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a mouse model of NASH
    Lefebvre, E.
    Hashiguchi, T.
    Jenkins, H.
    Nabhan, A.
    Yoneyama, H.
    Friedman, S. L.
    Wolfgang, G. H. I.
    ANTIVIRAL THERAPY, 2013, 18 : A14 - A15
  • [33] Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist
    Zheng, Changsheng
    Cao, Ganfeng
    Xia, Michael
    Feng, Hao
    Glenn, Joseph
    Anand, Rajan
    Zhang, Ke
    Huang, Taisheng
    Wang, Anlai
    Kong, Ling
    Li, Mei
    Galya, Laurine
    Hughes, Robert O.
    Devraj, Rajesh
    Morton, Phillip A.
    Rogier, D. Joseph
    Covington, Maryanne
    Baribaud, Fred
    Shin, Niu
    Scherle, Peggy
    Diamond, Sharon
    Yeleswaram, Swamy
    Vaddi, Kris
    Newton, Robert
    Hollis, Greg
    Friedman, Steven
    Metcalf, Brian
    Xue, Chu-Biao
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1442 - 1446
  • [34] WXSH0213, a dual CCR2 and CCR5 antagonist, ameliorates nonalcoholic activity score and liver fibrosis in MCD mice
    Wang, Jianhua
    Luo, Yunfu
    Ba, Yuyong
    Guo, Fengxun
    Xu, Deming
    Li, Jian
    Chen, Shuhui
    Chen, Xiaoxin
    Liu, Xing
    Li, Haijun
    Liu, Zhuowei
    Long, Chaofeng
    HEPATOLOGY, 2017, 66 : 151A - 151A
  • [35] Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH
    Lefebvre, Eric
    Hashiguchi, Taishi
    Jenkins, Helen
    Nabhan, Antoun
    Yoneyama, Hiroyuki
    Friedman, Scott L.
    Wolfgang, Grushenka H.
    HEPATOLOGY, 2013, 58 : 221A - 222A
  • [36] Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
    Bowler, S.
    Siriwardhana, C.
    Mitchell, B. L.
    D'Antoni, M. L.
    Ogata-Arakaki, D.
    Souza, S.
    Yee, R.
    Gangcuangco, L. M. A.
    Chow, D. C.
    Ndhlovu, L. C.
    Shikuma, C.
    HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 123 - 129
  • [37] Dual Chemokine Receptor CCR2/CCR5 Antagonist Cenicriviroc Ameliorates Lipotoxicity-Induced Insulin Resistance and NASH in Mice
    Ota, Tsuguhito
    Chen, Guanliang
    Nagashimada, Mayumi
    DIABETES, 2019, 68
  • [38] THE DUAL CCR2/CCR5 ANTAGONIST CENICRIVIROC AMELIORATES STEATOHEPATITIS AND FIBROSIS IN VIVO BY INHIBITING THE INFILTRATION OF INFLAMMATORY MONOCYTES INTO INJURED LIVER
    Puengel, T.
    Krenkel, O.
    Mossanen, J.
    Longerich, T.
    Lefebvre, E.
    Trautwein, C.
    Tacke, F.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S160 - S160
  • [39] Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activityof Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
    Lefebvre, E.
    Gottwald, M.
    Lasseter, K.
    Chang, W.
    Willett, M.
    Smith, P. F.
    Somasunderam, A.
    Utay, N. S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (03): : 139 - 148
  • [40] Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naive Subjects
    Lalezari, Jacob
    Gathe, Joseph
    Brinson, Cynthia
    Thompson, Melanie
    Cohen, Calvin
    Dejesus, Edwin
    Galindez, Jorge
    Ernst, Jerome A.
    Martin, David E.
    Palleja, Sandra M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (02) : 118 - 125
12345